Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07520578
Recruiting Phase 3

EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO)

NCT07520578 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2026-03-24
Last updated
2026-09-18

Condition(s) studied

Colorectal Cancer Screening

Investigational drug(s) / intervention(s)

Usual care follow-up by CRCDCInformation leaflet about colonoscopy follow-upEndorsement of CRCDC letters from the GP

Usual care follow-up by CRCDC: 1. 6 months after positive test result: 1st reminder letter from the CRCDC if it has no information about a colonoscopy being performed 2. 12 months after positive test result: 2nd reminder letter from the CRCDC if it has no information about a colonoscopy being performed 3. 18 months after positive test result: 3rd reminder letter from the CRCDC if it has no information about a colonoscopy being performed

Information leaflet about colonoscopy follow-up: An information leaflet about colonoscopy follow-up will be sent in an early letter 7 days after positive test result, and though QR-codes in subsequent reminders.

Endorsement of CRCDC letters from the GP: Explicit mention of their general practitioner in letters and reminders sent by the CRCDC to individuals who have tested positive for colorectal cancer, including the information leaflet about colonoscopy or a link to this document (QR code).

Study summary

To be effective, organized colorectal cancer screening requires good adherence to diagnostic colonoscopy in the event of a positive test. In France, the rate of diagnostic colonoscopy following a positive colorectal cancer screening test is less than 85%, and the median delay is close to 90 days. After receiving their positive result from the laboratory, individuals with no known follow-up are contacted only six months later by the Regional Cancer Screening Coordination Centers (CRCDC) responsible for following up with individuals who have tested positive. To optimize follow-up with colonoscopy, earlier contact and information about colonoscopy appear to be necessary. The contribution of the general practitioner identified on the test could be an additional lever.

The SUIVICOLO study aims to evaluate the effectiveness on the rate of colonoscopies performed at 6 months of two strategies for optimizing the follow-up of positive results in comparison with control group C (current procedures of the CRCDC Centre Val de Loire without early letter).

The two strategies evaluated will be:

* Group B1: Sending an early letter signed by the CRCDC accompanied by information leaflet about colonoscopy
* Group B2: Sending an early letter co-signed by the CRCDC and the general practitioner (identified or provided by the patient on the test identification form) accompanied by information leaflet about colonoscopy.

These strategies will be compared to the current follow-up strategy in a three arm randomized controlled arm.

Eligibility

Sex
ALL
Min age
50 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Aged between 50 and 75 at the time of the positive colorectal cancer screening test * Residing in one of the departments of the Centre Val de Loire region * Date on which the positive CRC screening test result was sent to the beneficiary recorded * Colorectal cancer screening test results sent to the beneficiary within 30 days of the test being read * Affiliated with a health insurance fund Exclusion Criteria: * Subjects who have notified their refusal to allow their data to be used for research purposes will be excluded from the analyses.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Crcdc-Cvl Tours France Recruiting

More University Hospital, Caen trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07520578 on ClinicalTrials.gov ↗ ← All trials in France